Conversely, elevated KANK2 mRNA expression was noted in cholangiocarcinoma (CHOL), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and pancreatic adenocarcinoma (PAAD) (p < 0.001), with significance in HNSC at p < 0.01. This evidence concerns the gene KANK2 and cholangiocarcinoma.